Researchers describe the occurrence of an outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) among healthcare workers and characterize at-risk exposures to improve future infection control interventions.
Michael Osterholm discusses the threat of Middle East respiratory syndrome (MERS) on a larger scale and what can be done to prevent it.
This increases the cases to 1,622, including 695 deaths since 2012.
Inovio Pharmaceuticals and GeneOne Life Sciences have started human testing of their Middle East respiratory syndrome (MERS) vaccine in South Korea.
The infection was reported in a 54-year-old male from Musannah.
As Middle East respiratory syndrome coronavirus (MERS-CoV) risk-standardized mortality rates are currently unavailable, the author sought to develop a method to estimate the risk-standardized mortality rates using MERS-CoV three and 30 day mortality measures.
Since August 24, six new cases of Middle East respiratory syndrome (MERS) have been announced, five from Domat Al Jandal.
Eight of the cases were acquired from a health facility, 12 cases from direct contact with camels, and three cases are still under investigation.
The US Centers for Disease Control and Prevention (CDC) conducted conveyance contact investigations, made up of all passengers and crew from four international and domestic flights and one bus, for two imported Middle East respiratory syndrome (MERS) cases.
The new cases raise the country’s MERS-CoV total to 1,693 cases, 686 fatal.